Approving a Problematic Muscular Dystrophy Drug
- 13 December 2016
- journal article
- viewpoint
- Published by American Medical Association (AMA) in JAMA
- Vol. 316 (22), 2357-2358
- https://doi.org/10.1001/jama.2016.16437
Abstract
This Viewpoint discusses controversies surrounding the US Food and Drug Administration’s 2016 approval of eteplirsen for treatment of Duchenne muscular dystrophKeywords
This publication has 1 reference indexed in Scilit:
- Faculty Opinions recommendation of Eteplirsen for the treatment of Duchenne muscular dystrophy.Published by H1 Connect ,2016